NCM Boston | Oxford Nanopore Technologies
NCM Boston
A
)
Andreas CzechBioNTech, Germany
)
Alex KneubehlBaylor College of Medicine, USA
)
Anne-Sophie LebreCHU Reims, France
)
Ailsa MacCalmanUniversity of Exeter, UK
)
Anastasia McKinlayIndiana University & HHMI, USA
)
Amit MathurSanofi, USA
)
Ana PeresThe University of North Carolina at Chapel Hill, USA
)
Aaron VinyColumbia University Irving Medical Center, USA
)
Akelia Wauchope-OdumboAssociate Director, Technical Applications — Americas, Oxford Nanopore Technologies
B
)
Bronya BoydonMachine Learning Bioinformatician, Oxford Nanopore Technologies
)
Bradley HallAsuragen, USA
)
Bryan LelandBioinformatics Manager, Commercial Applications, Oxford Nanopore Technologies
)
Benjamin C. ReinerUniversity of Pennsylvania, USA
)
Brynja SigurpálsdóttirdeCODE genetics, Iceland
C
)
Cory BernhardsDEVCOM Chemical Biological Center, USA
)
Chris BrownVP Strategic Programmes, Oxford Nanopore Technologies
)
Colette CôtéPathoQuest, USA
)
Christian GallardoSeattle Children's Research Institute, USA
)
Carol GreiderUniversity of California, Santa Cruz, USA
)
Chun-Chieh LinDartmouth Health, USA
)
Chad PollardWasatch BioLabs, USA
)
Charles A. SwoffordMIT Center for Biomedical Innovation, USA
)
Carly TyerApplications Scientist, Oxford Nanopore Technologies
)
Carika WeldonCariGenetics, Bermuda
D
)
Daniel K. FabianLonza, UK
)
Dan FordhamDirector, Strategic Product Management EMEA, Oxford Nanopore Technologies
)
Daniel KimUniversity of California, Santa Cruz, USA
)
Dmitrijs RotsErasmus MC, Netherlands
)
David VanHouteRegeneron Pharmaceuticals, USA
)
David YarmoshATCC, USA
)
)
G
)
Gabriela PozoUniversity of San Francisco de Quito, Ecuador
)
Gordon SangheraCEO, Oxford Nanopore Technologies
)
Gaston VondenhoffLonza, The Netherlands
H
)
Heather CarletonCenters for Disease Control & Prevention, USA
)
Helen GunterThe BASE Facility, The University of Queensland, Australia
J
)
Jessica AndersonSenior Field Applications Scientist, Oxford Nanopore Technologies
)
Justin BeckerDana-Farber Cancer Institute & Massachusetts General Hospital, USA
)
Jade BartoloAssociate Director, Automation, Oxford Nanopore Technologies
)
Jack ColicchioSound Agriculture, USA
)
Julie CollensVP, Commercial Operations AMR, Oxford Nanopore Technologies
)
Jimmy CreithField Applications Scientist, Bioinformatics, Oxford Nanopore Technologies
)
J. (Gus) GustafsonUniversity of Washington, USA
)
Julie HaendigesU.S. Food and Drug Administration, USA
K
)
Karine ChoquetUniversity of Sherbrooke, Canada
)
Keith ConnollyModalis Therapeutics, USA
)
Kamil KhanipovThe University of Texas Medical Branch, USA
)
Katherine LawrenceMachine Learning and Bioinformatics Manager, Oxford Nanopore Technologies
L
)
Lucia DaxingerLeiden University Medical Center, Netherlands
)
Lantana GrubVanderbilt University, USA
)
Lakmal JayasingheSenior VP, R&D Biologics, Oxford Nanopore Technologies
)
Laura KamenetzkyCONICET, Argentina
)
Logan MulroneyEMBL-EBI, UK & IIT, Italy
M
)
Matthew BainbridgeRady Children's Institute for Genomic Medicine, USA
)
Michael DeanNational Cancer Institute, USA
)
Mathilde FilserCurie Institute, France
)
Megan L. NoonanWashington University School of Medicine in St. Louis, USA
)
Matt ParkerDirector, Clinical Bioinformatics Software, Oxford Nanopore Technologies
)
Mile SikicGenome Institute of Singapore, A*STAR, Singapore
)
Mike VellaSenior Director, Machine Learning, Oxford Nanopore Technologies
)
)
P
)
Philipp ReschenederSenior Director, Applications Bioinformatics, Oxford Nanopore Technologies
)
Paula SaffieClinica Santa María, Chile
)
R
)
Ranjith AnandeGenesis, USA
)
Rachel O’NeillUniversity of Connecticut, USA
)
Rachel RubinsteinTechnical Product Manager, Software, Oxford Nanopore Technologies
)
Rosemary Sinclair DokosSenior VP, Product and Programme Management, Oxford Nanopore Technologies
)
Radhakrishna TirumalaiMerck & Co., USA
)
Rhydian WindsorResearch Scientist, Machine Learning, Oxford Nanopore Technologies
S
)
Stacy L. SpringsMIT Center for Biomedical Innovation, USA
)
Stephanie AbernathyVice President, Sales, Americas, Oxford Nanopore Technologies
)
Stephanie ChrysanthouMemorial Sloan Kettering Cancer Center, USA
)
Scott HickeyDirector, Commercial Applications, Oxford Nanopore Technologies
)
Shilpa KobrenHarvard Medical School, USA
)
Serge MonpoehoRegeneron Pharmaceuticals, USA
)
Svetlana MadjunkovaCReATe Fertility Centre, Canada
)
Sean McKenzieAssociate Director, Genomic Applications Bioinformatics, Oxford Nanopore Technologies
)
Samuel ShelburneThe University of Texas MD Anderson Cancer Center, USA
)
Sebastian B. TeitzveryTeitz Consulting, Germany
T
)
Thomas GarciaBaylor College of Medicine, USA
)
Tasos GogakosArena BioWorks & Massachusetts General Hospital, USA
)
Tim WalkerApplied Industrial Support Specialist, Oxford Nanopore Technologies
)
)
)
Oxford Nanopore Technologies
Bradley Hall
)
- Job title
- Institution
- Asuragen, USA
- Biography
Bradley Hall received his PhD in molecular biology from The University of Texas in 2008. There, he developed the Aptamer Stream within the Freshman Research Initiative, the largest undergraduate research program in the US. He transitioned to Altermune Technologies in 2010, founded by Nobel laureate Kary Mullis, where he focused on immune-redirecting therapies. In 2016, Brad joined Asuragen where he is currently Director of R&D with work focused on advancing nanopore sequencing in clinical laboratories with accessible testing kits.
- Recent publications
Hall, B. et al. A dual-mode targeted nanopore sequencing assay for comprehensive SMN1 and SMN2 variant analysis. medRxiv 2024.02.22.24303180; (2024).
DOI: 10.1101/2024.02.22.24303180Hall B. et al. Multisite Verification of a Targeted CFTR Polymerase Chain Reaction/Capillary Electrophoresis Assay That Evaluates Pathogenic Variants Across Diverse Ethnic and Ancestral Groups. Arch Pathol Lab Med. (2024).
DOI: 10.5858/arpa.2023-0230-OA.